Abstract

Sepsis, a dysregulated host response to infection characterized by organ failure, is one of the leading causes of death worldwide. Disbalances of the immune response play an important role in its pathophysiology. Patients may develop simultaneously or concomitantly states of systemic or local hyperinflammation and immunosuppression. Although a variety of effective immunomodulatory treatments are generally available, attempts to inhibit or stimulate the immune system in sepsis have failed so far to improve patients' outcome. The underlying reason is likely multifaceted including failure to identify responders to a specific immune intervention and the complex pathophysiology of organ dysfunction that is not exclusively caused by immunopathology but also includes dysfunction of the coagulation system, parenchymal organs, and the endothelium. Increasing evidence suggests that stratification of the heterogeneous population of septic patients with consideration of their host response might led to treatments that are more effective. The purpose of this review is to provide an overview of current studies aimed at optimizing the many facets of host response and to discuss future perspectives for precision medicine approaches in sepsis.

MeSH

Sepsis, Infections, Immunosuppression Therapy, Biomarkers, Therapeutics, Precision Medicine

Cited by

• The Mechanisms of Sepsis Induced Coagulation Dysfunction and Its Treatment. J Inflamm Res, 2025
• Advances and Challenges in Sepsis Management: Modern Tools and Future Directions. Cells, 2024
• Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock. Crit Care, 2024
• Recent Advances in Pathogenesis and Anticoagulation Treatment of Sepsis-Induced Coagulopathy. J Inflamm Res, 2025
• The effect of therapeutic plasma exchange on the inflammatory response in septic shock: a secondary analysis of the EXCHANGE-1 trial. Intensive Care Med Exp, 2025
• Rapid and Differential Diagnosis of Sepsis Stages Using an Advanced 3D Plasmonic Bimetallic Alloy Nanoarchitecture-Based SERS Biosensor Combined with Machine Learning for Multiple Analyte Identification. Adv Sci (Weinh), 2025
• Biomarkers to guide sepsis management. Ann Intensive Care, 2025
• Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients' Prognosis. Antibiotics (Basel), 2024
• Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy. Signal Transduct Target Ther, 2025
• Hemoadsorption in the Management of Septic Shock: A Systematic Review and Meta-Analysis. J Clin Med, 2025
• Evolving Paradigms in Sepsis Management: A Narrative Review. Cells, 2024
• Multi-Omics and -Organ Insights into Energy Metabolic Adaptations in Early Sepsis Onset. Adv Sci (Weinh), 2025
• Predictive value of combined inflammatory markers for septic cardiomyopathy: a retrospective study. BMC Infect Dis, 2025
• A novel, rapid, and practical prognostic model for sepsis patients based on dysregulated immune cell lactylation. Front Immunol, 2025
• Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial. BMJ Open, 2024
• Elevated free cholesterol levels due to impaired reverse cholesterol transport are a risk factor for polymicrobial sepsis in mice. J Biol Chem, 2025
• Identifying a unique signature of sepsis in patients with pre-existing cirrhosis. Crit Care, 2025
• Sepsis with Cancer is Marked by a Dysregulated Myeloid Cell Compartment: A Pilot Study. J Inflamm Res, 2025
• Serum mitochondrial-encoded NADH dehydrogenase 6 and Annexin A1 as novel biomarkers for mortality prediction in critically ill patients with sepsis. Front Immunol, 2024
• Unfractionated Heparin Enhances Sepsis Prognosis Through Inhibiting Drp1-Mediated Mitochondrial Quality Imbalance. Adv Sci (Weinh), 2024